Report cover image

Middle East Imaging Biomarkers Market Size, Share & Trends Analysis Report By Biomarkers (Molecular/Nuclear Biomarkers), By Imaging Technology, By Application, By End Use, By Country, And Segment Forecasts, 2025 - 2033

Publisher Grand View Research
Published Nov 07, 2025
Length 120 Pages
SKU # GV20649526

Description

Market Size & Trends

The Middle East imaging biomarkers market size was estimated at USD 413.74 million in 2024 and is projected to reach USD 1,131.80 million by 2033, growing at a CAGR of 12.27% from 2025 to 2033. The expansion of advanced imaging infrastructure (MRI, PET/CT) and the greater adoption of biomarker-driven clinical pathways are shifting care from empiric to data-driven approaches.

This structural shift-driven by national healthcare strategies, increased public and private healthcare spending, and programs aimed at attracting clinical trials-creates a growing addressable market for imaging biomarkers used in oncology, neurology, and cardiology.

The growing prevalence of chronic and lifestyle-related diseases is one of the most significant drivers of the Middle East imaging biomarkers industry. The region has seen a rapid rise in cancer, cardiovascular, and neurological disorders due to aging populations, sedentary lifestyles, and dietary changes. According to WHO data, noncommunicable diseases account for over 70% of total deaths in GCC countries, increasing the need for early detection and precise diagnosis. Imaging biomarkers-used in PET, MRI, and CT modalities-play a vital role in identifying disease progression at the molecular levels. This surge in chronic disease prevalence has, therefore, heightened demand for advanced imaging technologies that rely on biomarker data for early and accurate diagnosis.

Increasing healthcare expenditure and infrastructure development are also accelerating market growth. Countries such as Saudi Arabia, the UAE, and Qatar are investing heavily in advanced diagnostic centers, imaging equipment, and hospital modernization as part of their national health transformation programs. For example, Saudi Arabia’s Vision 2030 allocates substantial funds to expand digital and diagnostic healthcare capabilities, while the UAE continues to position itself as a regional hub for precision medicine and advanced diagnostics. This sustained increase in healthcare spending-estimated to grow at over 7% annually across the GCC-enhances accessibility to imaging biomarker technologies and fuels adoption across both public and private sectors.

Middle East Imaging Biomarkers Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the Middle East imaging biomarkers market report based on biomarkers, imaging technology, application, end use, and country:
  • Biomarkers Outlook (Revenue, USD Million, 2021 - 2033)
  • Anatomical biomarkers
  • Functional biomarkers
  • Molecular/Nuclear Biomarkers
  • Quantitative Imaging Biomarkers
  • Others
  • Imaging Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • MRI
  • CT
  • PET
  • SPECT
  • Ultrasound
  • Others
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Diagnostics
  • Drug Discovery & Development
  • Personalized Medicine
  • Disease Risk Assessment
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Diagnostic/imaging centers
  • Pharmaceutical and Biotech Companies
  • Others
  • Country Outlook (Revenue, USD Million, 2021 - 2033)
  • Middle East
  • Saudi Arabia
  • UAE
  • Kuwait
  • Oman
  • Qatar
Please note The report will be delivered in 2-3 business days upon order notification.

Table of Contents

120 Pages
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Biomarkers
1.2.2. Imaging Technology
1.2.3. Application
1.2.4. End Use
1.3. Information analysis
1.4. Market formulation & data visualization
1.5. Data validation & publishing
1.6. Information Procurement
1.6.1. Primary Research
1.7. Information or Data Analysis
1.8. Market Formulation & Validation
1.9. Market Model
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising demand for early diagnosis and personalized medicine
3.2.1.2. Advancements in imaging and molecular biomarker technologies
3.2.1.3. Regulatory approvals supporting clinical adoption
3.2.2. Market Restraint Analysis
3.2.2.1. High cost of imaging equipment and diagnostic tests
3.3. Industry Analysis Tools
3.3.1. Porter's Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Middle East Imaging Biomarkers Market: Biomarkers Business Analysis
4.1. Segment Dashboard
4.2. Middle East Imaging Biomarkers Market Biomarkers Movement Analysis
4.3. Middle East Imaging Biomarkers Market Size & Trend Analysis, by Biomarkers, 2021 to 2033(USD Million)
4.4. Anatomical Biomarkers
4.4.1. Anatomical Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Functional Biomarkers
4.5.1. Functional Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Molecular/Nuclear Biomarkers
4.6.1. Molecular/Nuclear Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. Quantitative Imaging Biomarkers
4.7.1. Quantitative Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.8. Others
4.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Middle East Imaging Biomarkers Market: Imaging Technology Business Analysis
5.1. Segment Dashboard
5.2. Middle East Imaging Biomarkers Market Imaging Technology, Movement Analysis
5.3. Middle East Imaging Biomarkers Market Size & Trend Analysis, by Imaging Technology, 2021 to 2033(USD Million)
5.4. MRI
5.4.1. MRI Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. CT
5.5.1. CT Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. PET
5.6.1. PET Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. SPECT
5.7.1. SPECT Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.8. Ultrasound
5.8.1. Ultrasound Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.9. Others
5.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Middle East Imaging Biomarkers Market: Application Business Analysis
6.1. Segment Dashboard
6.2. Middle East Imaging Biomarkers Market Application Movement Analysis
6.3. Middle East Imaging Biomarkers Market Size & Trend Analysis, by Application, 2021 to 2033(USD Million)
6.4. Diagnostics
6.4.1. Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Drug Discovery & Development
6.5.1. Drug Discovery & Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Personalized Medicine
6.6.1. Personalized Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Disease Risk Assessment
6.7.1. Disease Risk Assessment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. Others
6.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Middle East Imaging Biomarkers Market: End Use Business Analysis
7.1. Segment Dashboard
7.2. Middle East Imaging Biomarkers Market End Use Movement Analysis
7.3. Middle East Imaging Biomarkers Market Size & Trend Analysis, by End Use, 2021 to 2033(USD Million)
7.4. Hospitals
7.4.1. Hospitals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Diagnostic/imaging centers
7.5.1. Diagnostic/imaging centers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Pharmaceutical and Biotech Companies
7.6.1. Pharmaceutical and Biotech Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. Others
7.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Middle East Imaging Biomarkers Market: Country Estimates & Trend Analysis by Biomarkers, Imaging Technology, Application & End Use
8.1. Country Dashboard
8.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
8.3. Middle east
8.3.1. Middle East Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.3.2. Saudi Arabia
8.3.2.1. Key Country Dynamics
8.3.2.2. Competitive Scenario
8.3.2.3. Regulatory Framework
8.3.2.4. Saudi Arabia Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.3.3. UAE
8.3.3.1. Key Country Dynamics
8.3.3.2. Competitive Scenario
8.3.3.3. Regulatory Framework
8.3.3.4. UAE Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.3.4. Kuwait
8.3.4.1. Key Country Dynamics
8.3.4.2. Competitive Scenario
8.3.4.3. Regulatory Framework
8.3.4.4. Kuwait Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.3.5. Oman
8.3.5.1. Key Country Dynamics
8.3.5.2. Competitive Scenario
8.3.5.3. Regulatory Framework
8.3.5.4. Oman Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.3.6. Qatar
8.3.6.1. Key Country Dynamics
8.3.6.2. Competitive Scenario
8.3.6.3. Regulatory Framework
8.3.6.4. Qatar Imaging Biomarkers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant Categorization
9.2. Strategy Mapping
9.3. Company Market Position Analysis, 2024
9.4. Participant’s Overview
9.4.1. GE HealthCare
9.4.1.1. Overview
9.4.1.2. Financial Performance
9.4.1.3. Biomarkers Benchmarking
9.4.1.4. Strategic Initiatives
9.4.2. FUJIFILM Holdings Corporation
9.4.2.1. Overview
9.4.2.2. Financial Performance
9.4.2.3. Biomarkers Benchmarking
9.4.2.4. Strategic Initiatives
9.4.3. Siemens Healthineers AG
9.4.3.1. Overview
9.4.3.2. Financial Performance
9.4.3.3. Biomarkers Benchmarking
9.4.3.4. Strategic Initiatives
9.4.4. Lunit Inc.
9.4.4.1. Overview
9.4.4.2. Financial Performance
9.4.4.3. Biomarkers Benchmarking
9.4.4.4. Strategic Initiatives
9.4.5. Median Technologies
9.4.5.1. Overview
9.4.5.2. Financial Performance
9.4.5.3. Biomarkers Benchmarking
9.4.5.4. Strategic Initiatives
9.4.6. BioClinica Inc.
9.4.6.1. Overview
9.4.6.2. Financial Performance
9.4.6.3. Biomarkers Benchmarking
9.4.6.4. Strategic Initiatives
9.4.7. ICON plc
9.4.7.1. Overview
9.4.7.2. Financial Performance
9.4.7.3. Biomarkers Benchmarking
9.4.7.4. Strategic Initiatives
9.4.8. Bracco
9.4.8.1. Overview
9.4.8.2. Financial Performance
9.4.8.3. Biomarkers Benchmarking
9.4.8.4. Strategic Initiatives
9.4.9. Philips Healthcare
9.4.9.1. Overview
9.4.9.2. Financial Performance
9.4.9.3. Biomarkers Benchmarking
9.4.9.4. Strategic Initiatives

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us